Celanese (CE)
(Delayed Data from NYSE)
$152.04 USD
+0.72 (0.48%)
Updated May 31, 2024 04:00 PM ET
After-Market: $152.06 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth B Momentum C VGM
Brokerage Reports
Celanese Corporation [CE]
Reports for Purchase
Showing records 181 - 200 ( 470 total )
Company: Celanese Corporation
Industry: Chemical - Diversified
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Company: Celanese Corporation
Industry: Chemical - Diversified
Company: Celanese Corporation
Industry: Chemical - Diversified
2Q20 Follow-Up - Execution in Acetyls Deserves Credit
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
3Q Outlook Better Than Consensus with Acetyls Outperforming, EM in Line
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Company: Celanese Corporation
Industry: Chemical - Diversified
Sale of Polyplastics JV Adds Estimated $6-$7 of Value per Share
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Consumer/Retail Hardlines: June Retail Sales Above Expectations, Improvement Continues
Provider: KEYBANC CAPITAL MARKETS
Analyst: THOMAS B
Company: Celanese Corporation
Industry: Chemical - Diversified
Company: Celanese Corporation
Industry: Chemical - Diversified
Chemicals 2Q Preview: Our Conviction on OW Names Remains High
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Company: Celanese Corporation
Industry: Chemical - Diversified
Recent Dip in VAM Benchmark Margins Is a Risk for 2Q/3Q Numbers, in Our View
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Provider: Zacks Investment Research
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Company: Celanese Corporation
Industry: Chemical - Diversified
Acetyls Tracking a Bit Better Than Expected; We Re-examine Mid-cycle Earnings and Valuation
Provider: KEYBANC CAPITAL MARKETS
Analyst: Research Department
Company: Celanese Corporation
Industry: Chemical - Diversified
Provider: Zacks Investment Research
Analyst: Research Department